Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue

16 May 2025

Abstract excerpt

Dengue virus (DENV) threatens public health, especially in regions with tropical and subtropical climates. In 2024, the World Health Organisation reported 3.4 million confirmed dengue cases, with 16,000 severe cases and 3000 dengue-associated fatalities. The first licensed dengue vaccine, CYD-TDV (Dengvaxia®,Sanofi-Pasteur, Paris, France), is recommended by the WHO only for individuals aged 9–45 years with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mosquito-borne diseases and control
Share to Viral Infections and Vectors
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40432141
DOI: 10.3390/vaccines13050532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against DenguePMID 40432141Read ↗

Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.Semantic proximity Read ↗

Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.Semantic proximity Read ↗

An In Silico Design of a Vaccine against All Serotypes of the Dengue Virus Based on Virtual Screening of B-Cell and T-Cell EpitopesSemantic proximity Read ↗

Fusion Loop Modified and Mature Dengue Virus Elicits Protective Serum with Minimal Antibody Dependent EnhancementSemantic proximity Read ↗

The Conserved Molecular Determinants of Virulence in Dengue VirusSemantic proximity Read ↗

Host Immune Response to Dengue Virus Infection: Friend or Foe?Semantic proximity Read ↗

In silico design and evaluation of multi-epitope dengue virus vaccines: a promising approach to combat global dengue burdenSemantic proximity Read ↗

mRNA-LNP Vaccines Encoding for Dengue Optimized prM/ENV Proteins Induce Protective Immunity without ADESemantic proximity Read ↗

Exploring Dengue Infection in a Vaccinated Individual: Preliminary Molecular Diagnosis and Sequencing InsightsSemantic proximity Read ↗

Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human ChallengeSemantic proximity Read ↗

Approaches of dengue control: vaccine strategies and future aspectsSemantic proximity Read ↗

A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.